Phase II most common among immuno-oncology trials, 2008-2017

18th May 2018 (Last Updated May 18th, 2018 12:06)

GlobalData has reviewed the phase of global clinical trials in the immuno-oncology (IO) space that were initiated between 2008 and 2017. For the purposes of this analysis, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

GlobalData has reviewed the phase of global clinical trials in the immuno-oncology (IO) space that were initiated between 2008 and 2017. For the purposes of this analysis, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Overall, Phase II trials outnumbered all other phases by contributing 52%–62% across the period. The share of Phase I trials remained at around 31% across the 10-year period, as shown in Figure 1. Phase III trials’ contribution marginally increased from 7% to 9%, whereas Phase IV trials’ share remained flat at approximately 3%.

In absolute numbers, Phase III studies have grown faster than all other phases across the ten-year period, followed by Phase II, Phase I, and Phase IV. For multiple-year intervals, the growth in Phase III trials has been most prominent from 2013 onwards. Among Phase III, pivotal/registration studies have grown 15 times between 2008 and 2017. This shows that, in spite of the relatively low contribution of Phase III trials, interventions are increasingly progressing towards approval.

Figure 1: Global IO clinical trials by phase. Credit: GlobalData.

For more insight and data, visit the GlobalData Report Store - Drug Development Technology is part of GlobalData Plc.